The present invention relates to the composition of medicine comprising human interleukin 2 (hIL-2) monoclonal antibody specific (mAb) or its antigen-binding fragment and immunologic test point inhibitor, the combination of human interleukin 2 (hIL-2) monoclonal antibody specific (mAb) or its antigen-binding fragment and hIL-2 inhibit the combination of hIL-2 and CD25. HIL-2 antibody can not be given together with recombination hIL-2, and be characterized in that any following parameter: the variable chains of mAb include amino acid sequence SEQ ID NO 005 or SEQ ID NO 006 It is described to be dissociation constant (KD)≤7. with hIL-2 binding characteristic5nmol/L It is described to be that dissociation rate (Koff)≤1 × 10-4s-1 and/or the antibody show undeterminable cross reactivity to muroid IL-2 with hIL-2 binding characteristic.
